TABLE 1

Characteristics of Study Population

Patient no.	Age (y)	Sex	Tumor location	Tumor grade^*	Tumor growth fraction^† (%)	Indication
1	64	F	Hindgut NET	G3	70	Restaging
2	37	M	Pancreatic NET	G3	30	Restaging
3	73	M	Midgut NET	G2	3	Restaging
4	62	M	Pancreatic NET	G1	1	Restaging
5	59	M	Midgut NET	G2	5	Restaging
6	51	M	Midgut NET	G1	<1	Staging
7	65	F	Midgut NET	G2	15	Restaging
8	69	F	Hindgut NET	G2	15	Restaging
9	63	M	Unknown primary	G3	50	Staging
10	67	F	Pancreatic NET	G1	<2	Staging
11	57	F	Pancreatic NET	G2	5	Restaging
12	44	M	Pancreatic NET	G3	>20	Restaging
13	71	M	Hindgut NET	G3	90	Staging
14	41	M	Pancreatic NET	G2	15	Staging
15	80	F	Midgut NET	G3	40	Staging
16	46	F	Midgut NET	G1	<2	Staging
17	56	M	Foregut NET	G2	<20	Restaging
18	54	F	Pancreatic NET	G3	33	Restaging

↵* According to European Neuroendocrine Tumor Society proposal for grading GEP-NETs (21).
↵† Ki-67 index was used to determine tumor growth fraction.